WILMINGTON, Mass., May 2, 2016 /PRNewswire/ — Implant Sciences Corporation (OTCQB: IMSC), a leading manufacturer of explosives trace detection (ETD) solutions for Department of Homeland Security applications, announced today that it is one of the 16 companies that have been selected by the Department of Homeland Security (DHS) to receive the 2016 DHS Small Business Achievement Award for its outstanding work in support of the DHS’ stated mission to help ensure a homeland that is safe, secure, and resilient against terrorism and other hazards.

According to DHS, Implant Sciences was honored for its “excellent support to TSA and being responsive to a changing environment and working hard to meet requirements while providing excellent service.” Robert Liscouski, President of Implant Sciences, received the award on behalf of the company on Thursday, April 21, 2016 at a ceremony held at DHS offices in Washington, D.C.

“At Implant Sciences, service is in our culture. We strive to provide first level support for systems in our home country and all over the world, and we are proud to accept this DHS Small Business Achievement Award on behalf of all our employees for their tireless dedication and commitment to quality,” stated Dr. Bill McGann, Implant Sciences’ CEO.

“The fact that we were nominated for this award due to our work with TSA, our biggest customer to date, is something we are truly excited about,” added Robert Liscouski, Implant Sciences’ President. “We aim to be responsive to the needs of our customers, and our commitment to them extends far beyond shipping the order.”

About DHS Small Business Achievement Awards

The annual DHS Small Business Achievement Award recognizes exceptional contributions to the homeland security mission by a select group of small business firms from across the country. The award is sponsored by the DHS Office of Small and Disadvantaged Business Utilization (OSDBU) and includes nominations and substantial participation by the broader DHS procurement community and program offices in DHS components.

About the QS-B220 Desktop Explosives Trace Detector

The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.

About the QS-H150 Handheld Explosives Trace Detector

The QS-H150 utilizes Ion Mobility Spectrometry (IMS) technology, providing fast, accurate detection of trace amounts of a wide variety of military, commercial, and homemade explosives. Built with no radioactive materials and featuring a low-maintenance, self-calibrating, and self-clearing design, the QS-H150 provides very high levels of operational availability. The QS-H150 has been proven to perform well in a wide variety of temperatures and challenging environments, from humid jungles to dry, sand swept deserts.

About Implant Sciences

Implant Sciences is a leader in developing and manufacturing advanced detection capabilities to counter and eliminate the ever-evolving threats from explosives and drugs. The company’s team of dedicated trace detection experts has developed proprietary technologies used in its commercial products, thousands of which have been sold across more than 70 countries worldwide. The company’s ETDs have received approvals and certifications from several international regulatory agencies including the TSA in the U.S., ECAC in Europe, CAAC and the Ministry of Public Safety in China, Russia FSB, STAC in France, and the German Ministry of the Interior. It has also received the 2015 GSN Airport/Seaport/Border Security Award for “Best Security Checkpoint”. For further details on the Company and its products, please visit the Company’s website at www.implantsciences.com.

Cautionary Note Regarding Forward-Looking Statements

This press release and any statements of employees, representatives and partners of Implant Sciences Corporation (the “Company”) related thereto contain or may contain certain “forward-looking statements,” as that term is defined in the Private Securities Litigation Reform Act of 1995.  Such statements may include, without limitation, statements with respect to the Company’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential” or similar expressions.  Such statements are based on management’s current expectations and are subject to significant risks and uncertainties (many of which are beyond the Company’s control) that could cause the Company’s actual results to differ materially from the forward-looking statements.  Such risks and uncertainties include, but are not limited to (i) the risk that the Company’s strategic initiatives referenced herein may not actually occur, or if they occur, that they will not benefit the Company’s shareholders, (ii) the risk that deployment of the Company’s devices may not occur as planned, (ii) the risk that there is no guaranty that the Transportation Security Administration (TSA) or any other U.S. or foreign government and law enforcement agencies or commercial consumers will purchase any of the Company’s explosives detection products or that any new products the Company may develop will be accepted by the TSA or by such other governments, agencies or consumers, (iii) economic, political and other risks associated with international sales and operations could adversely affect the Company’s sales, (iv) the Company’s business is subject to intense competition and rapid technological change, and the Company’s ability to generate revenue and profit will depend on its ability to develop and introduce new products and (v) other risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K.  In light of these risks and uncertainties, readers are cautioned that actual results may differ significantly from those described or anticipated in the forward-looking statements.  The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.

Contact:

Implant Sciences Corporation
Company Contact:
Robert Liscouski
978-752-1700 x 116

Add a Comment to this Post

comments

SHARE